Solar for UK pharmaceutical manufacturing — funding routes and GMP-compliant delivery.

UK pharma manufacturing — exceptional solar economics with operational complications

UK pharmaceutical manufacturing has substantial decarbonisation pressure and unusually strong solar economics. Three structural drivers: (1) electricity demand is exceptional — purification, cleanroom HVAC, sterilisation and cold chain all require continuous high electricity loads; (2) operational continuity is 24/7, producing self-consumption rates of 85-95% on properly sized PV systems; (3) major UK pharma manufacturers have public net zero commitments backed by substantial capital programmes.

The complications are operational rather than economic. GMP compliance affects how PV install can be sequenced around production schedules. Cleanroom HVAC plant on the roof reduces useful unobstructed area for PV. And the cold chain criticality of many pharma processes means solar plus battery integration becomes a resilience question, not just an economic one.

The 2026 funding stack for UK pharma manufacturing

Scottish pharma (GSK Montrose, Piramal Grangemouth, others)

SIETF remains active and is the strongest direct grant route. Up to 30% of capex (50% for deep decarbonisation including process electrification). Stack with Full Expensing on net of grant + 0% VAT + SEG.

English pharma (the majority of UK pharma)

English IETF closed for new applications. Active stack: Full Expensing + 0% VAT + SEG + PPA + (for sites in eligible Mayoral Authority areas) Local Growth Fund. PPA is the dominant route at multi-MWp scale because of operator covenant strength.

Welsh and NI pharma

Welsh Industrial Decarbonisation (Welsh sites) and Invest NI Capital Grants (Almac, Norbrook). Both have funded several pharma manufacturing decarbonisation packages since 2022.

Major UK pharma manufacturers and their solar programmes

GSK

UK manufacturing sites include Barnard Castle (antibiotics, respiratory), Ulverston (vaccines), Ware (consumer healthcare), Worthing (oncology), Stevenage (R&D + commercial), Montrose (Scotland — APIs). Multi-site PV programme since 2022 funded through internal capital and IETF Phase 2/3 (where active). Multiple sites with multi-MWp solar deployment.

AstraZeneca

UK manufacturing at Macclesfield (oncology, cardiovascular), Luton (respiratory), Speke (small molecules). New Cambridge Discovery Centre opened with substantial integrated PV. Multi-site UK PV programme.

Pfizer

Sandwich (UK R&D and commercial). Solar deployment progressing under Pfizer global net zero commitment.

Eli Lilly

Speke (one of the largest UK pharma manufacturing sites — cytostatic injectables, insulin). PV deployment progressing since 2022 under combination of internal capital and IETF Phase 2.

Almac Group (Northern Ireland)

Craigavon (NI) and Edinburgh (Scotland) sites. Solar at both. Funded under DfE-administered NI Industrial Energy Transformation Programme and SIETF.

UK pharma supply chain

Tier-2 and tier-3 pharma suppliers — API manufacturers (Cambrex, Sterling Pharma, Dextra Labs), packaging specialists, cold-chain logistics, formulation specialists. Often more accessible for active 2026 funding routes than the major branded manufacturers (less internal capital availability, more grant dependency).

Worked example — UK pharma manufacturing site 2026

A typical UK pharma manufacturing site (formulation, packaging, distribution): 12 GWh/year electricity demand, 22,000 m² rooftop:

• System size: 1.8 MWp rooftop + 800kWh battery (cold-chain resilience)
• Headline capex: £1.32m PV + £360k battery = £1.68m total
• Full Expensing on full capex: £420,000 (25%)
• 0% VAT applied at install
• Net cost: £1.26m
• Annual savings (electricity displacement + SEG export): £385,000
• Payback: 3.3 years
• Battery resilience: 4-6 hours of cold-chain backup at typical refrigeration load

GMP compliance and install sequencing

Pharma manufacturing PV installs need GMP-aware contracting. Specifically:

• Roof access scheduling around production batch cycles
• Risk assessment for any ingress points near GMP areas
• Validation requirements for changes to electrical infrastructure feeding production areas
• Cleanroom HVAC plant — solar mounting must not interfere with airflow, particulate filtration access, or exhaust paths
• Audit trail documentation for the install

We work with MCS-certified installers who have GMP delivery experience — the bench is small but each major UK pharma manufacturing region has at least one capable EPC.

Related sector pages

• Solar grants for manufacturers — broader IETF context
• Food processing solar — adjacent regulated-manufacturing parallel
• Data centres solar — similar 24/7 critical-load profile
• Scottish IETF — for Scottish pharma
• Full Expensing — primary route for English pharma